AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca will invest US$50bn in the US to expand manufacturing and research
AstraZeneca shares show signs of life after successful trials of hypertension drug
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca - CNBC
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. https://t.co/b5hOwTxWaU https://t.co/Wq5EsZGLK5
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
221.9BUSD
Type
Common Stock
Aandelenbeurs
PINK
Valuta code
USD
Valutanaam
US Dollar
Naam van het land
USA
Land-ISO
US
IS IN
GB0009895292
CUSIP
-
Sector
Healthcare
Industrie
Drug Manufacturers - General
Einde boekjaar
December
IPO-datum
-
Bijgewerkt op
-
P / E verhouding
28.55
PEG-ratio
0.95
Boekwaarde
26.48
Dividendaandeel
3.1
Dividendrendement
2.22%
Winstaandeel
4.97
Richtprijs Wall Street
-
EPS-schatting huidig jaar
-
EPS-schatting volgend jaar
-
EPS-schatting huidig kwartaal
0
EPS-schatting volgend kwartaal
0
Meest recente kwartaal
-
Inkomsten TTM
54,982,000,640
Brutowinst TTM
45,328,998,400
EBITDA
18,276,999,168
Winstmarge
14.14%
Rendement op activa TTM
8.16%
Rendement op eigen vermogen TTM
19.79%
Opbrengst per aandeel TTM
35.467
Qtly omzetgroei op jaarbasis
7.20%
Verdunde Eps TTM
4.97
Qtly winstgroei op jaarbasis
33.60%
Achterlopende PE
28.55
Voorwaarts PE
15
Prijs Verkoop TTM
4.0009
Prijsboek MRQ
5.3602
Bedrijfswaarde-inkomsten
4
Bedrijfswaarde EBITDA
15
70.24
5.20%73.05
3.62%798.44
2.93%190.40
1.87%40.23
1.11%117.99
0.96%168.54
0.38%337.00
0.07%114.52
-3.52%317.30
-1.29%